Zobrazeno 1 - 10
of 5 987
pro vyhledávání: '"MEK-inhibitor"'
Publikováno v:
IJU Case Reports, Vol 7, Iss 5, Pp 375-378 (2024)
Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cys
Externí odkaz:
https://doaj.org/article/43651bcc73904f9e8352ec475a6407f4
Autor:
John R. Apps, Jose Mario Gonzalez-Meljem, Romain Guiho, Jessica C. Pickles, Eric Prince, Edward Schwalbe, Nikhil Joshi, Thomas J. Stone, Olumide Ogunbiyi, Jane Chalker, Akang Bassey, Georg Otto, Rosalind Davies, Debbie Hughes, Sebastian Brandner, Enrica Tan, Victoria Lee, Caroline Hayhurst, Cassie Kline, Sergi Castellano, Todd Hankinson, Timo Deutschbein, Thomas S. Jacques, Juan Pedro Martinez-Barbera
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-15 (2024)
Abstract The two types of craniopharyngioma, adamantinomatous (ACP) and papillary (PCP), are clinically relevant tumours in children and adults. Although the biology of primary craniopharyngioma is starting to be unravelled, little is known about the
Externí odkaz:
https://doaj.org/article/0874ef81d5794b778ecf6f36f0dcbfe2
Autor:
Mahdi Zahmatyar, Ladan Kharaz, Negin Abiri Jahromi, Ali Jahanian, Pourya Shokri, Seyed Aria Nejadghaderi
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Lung cancer, accounting for a significant proportion of global cancer cases and deaths, poses a considerable health burden. Non-small cell lung cancer (NSCLC) patients have a poor prognosis and limited treatment options due to lat
Externí odkaz:
https://doaj.org/article/2d99e752092b449fb0f60fa0bb9aea39
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 933-939 (2024)
Michelle M Dugan,1 Matthew C Perez,1 Lilit Karapetyan,1,2 Jonathan S Zager1,2 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa,
Externí odkaz:
https://doaj.org/article/4db836dc40d24c50a66256f8e81216ba
Autor:
Craig Erker, Magimairajan Issai Vanan, Valérie Larouche, Liana Nobre, Chantel Cacciotti, Stéphanie Vairy, Shayna Zelcer, Adam Fleming, Eric Bouffet, Nada Jabado, Geneviève Legault, Samuele Renzi, Tara McKeown, Bruce Crooks, Nirav Thacker, Vijay Ramaswamy, Hallie Coltin, Lucie Lafay-Cousin, Sylvia Cheng, Juliette Hukin, Seth Andrew Climans, Mary Jane Lim-Fat, Sarah McKillop, Sarah Lapointe, Mélanie Alves, Julie Bennett, Uri Tabori, Sébastien Perreault
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 4022-4029 (2024)
Background: The treatment of BRAF V600E gliomas with BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade gliomas (PLGGs) and pediatric high-grade gliomas (HGGs). However,
Externí odkaz:
https://doaj.org/article/18a6d0e5930647838048e65c909b0585
Autor:
Rashad Jabarkheel, Lun Li, Maxwell Frankfurter, Daniel Y. Zhang, Avi Gajjar, Najib Muhammad, Visish M. Srinivasan, Jan-Karl Burkhardt, Mark Kahn
Publikováno v:
Frontiers in Surgery, Vol 11 (2024)
Brain arteriovenous malformations (AVMs) are vascular lesions characterized by abnormal connections between parenchymal arteries and veins, bypassing a capillary bed, and forming a nidus. Brain AVMs are consequential as they are prone to rupture and
Externí odkaz:
https://doaj.org/article/acae64a62a1542f8abdb059480850807
Autor:
Edouard Romano, Sebastien Tran, Assma Ben Aissa, Miguel Carvalho Goncalves, André Durham, Pelagia Tsoutsou
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionSignificant therapeutic changes have recently occurred in the management of melanoma brain metastases (BMs), both in the field of local treatments, with the rise of stereotactic radiotherapy (RT), as well as in systemic ones, with the adv
Externí odkaz:
https://doaj.org/article/38957a770de44131b12bf88b821a73ea
Autor:
Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Background Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor with substantial clinical activities in patients with NRAS-mutant melanoma. This phase I study evaluated the safety and preliminary efficacy of tunlametinib plus vem
Externí odkaz:
https://doaj.org/article/0f192aa657bc4c0d996fc74a75cf28e7
Publikováno v:
Case Reports in Dermatology, Vol 16, Iss 1, Pp 133-139 (2024)
Introduction: The development of new and changing melanocytic lesions has been increasingly reported as an adverse dermatologic toxicity of BRAF inhibitor therapy. Melanocytic lesions and melanomas induced by BRAF inhibitor therapy that lack BRAF V60
Externí odkaz:
https://doaj.org/article/8d855a20e7da4480b0241ec7c5505142
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2644-2649 (2024)
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi th
Externí odkaz:
https://doaj.org/article/bfc15549bd604b2da56bae5c6c41126f